Camizestrant Recommended for Approval in the EU for Advanced ER-Positive Breast Cancer

Key Takeaways

• CHMP positive opinion for Etcamah (camizestrant) adopted 21 May 2026 (EMA/114517/2026).
• Proposed use: with palbociclib, ribociclib, or abemaciclib upon ESR1 mutation detection without progression on first-line AI + CDK4/6 therapy.
• Benefit claimed in the EMA product page: improved PFS versus continuing the same AI + CDK4/6 regimen after ESR1 emergence.
• SERENA-6 previously reported a 56% reduction in risk of progression or death in the camizestrant switch arm (AstraZeneca/NEJM-cited Phase III).

What did CHMP recommend for camizestrant?

On 21 May 2026, CHMP adopted a positive opinion recommending marketing authorisation for Etcamah (camizestrant) for ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients with ESR1 gene mutations.

The applicant is AstraZeneca AB. Etcamah is described as 75 mg film-coated tablets; camizestrant is an oral next-generation SERD and complete ER antagonist (ATC L02BA05).

Which patients are in the proposed indication?

EMA’s product page states Etcamah with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for adults with ER+/HER2− advanced disease upon ESR1-mutation detection and without disease progression during first-line endocrine therapy plus a CDK4/6 inhibitor.

CHMP meeting highlights for 18–21 May 2026 list the same ESR1-selected combination use; EC decision remained pending at highlight publication.

What evidence underpins the opinion?

The opinion leans on SERENA-6 Phase III. AstraZeneca reported camizestrant plus CDK4/6 inhibitor cut the risk of disease progression or death by 56% versus continuing AI + CDK4/6 after emergent ESR1 mutation; results were presented at ASCO 2025 and published in The New England Journal of Medicine per company disclosures cited on EMA materials.

• Opinion date: 21 May 2026
• Brand in EU file: Etcamah
• Dose form: 75 mg tablets

How does this differ from broad first-line ER+ claims?

Earlier secondary headlines framing “first-line advanced ER-positive breast cancer” omit the ESR1 biomarker gate and the switch design after AI + CDK4/6. Primary EMA text is biomarker-selected and progression-free on prior first-line combination therapy.

What remains unproven?

A CHMP opinion is not an EC marketing authorisation. Final SmPC wording, reimbursement, and real-world uptake after ESR1 ctDNA monitoring workflows still depend on the Commission decision and national HTA steps.

What should oncology BD track next?

Watch the EC decision timeline for Etcamah, U.S. Breakthrough Therapy follow-on filings, and competitor oral SERD programmes. Prefer EMA opinion PDFs and the Etcamah medicine page over unverified efficacy restatements.

How should EU oncology teams prepare for Etcamah?

If the European Commission grants authorisation, centres will need ESR1 mutation testing workflows that can detect emergence during first-line AI plus CDK4/6 therapy. SERENA-6’s switch design makes timing of the biomarker trigger as important as the drug itself.

Procurement and pharmacy teams should plan for 75 mg film-coated tablets and combination scheduling with palbociclib, ribociclib, or abemaciclib as labelled. Until the Commission decision posts, treat CHMP’s 21 May 2026 opinion as a high-probability but not final approval signal.

Related NovaPharma coverage

• Imfinzi perioperative bladder cancer
• DEFINITIVE HER2DX trial milestone
• EMA Management Board March 2026

Frequently Asked Questions

Primary Sources

1. EMA Etcamah (camizestrant) medicine page
2. CHMP meeting highlights 18–21 May 2026
3. CHMP summary of positive opinion — Etcamah